Broker Announcement

Oxford Biomedica PLC
09 November 2007




For Immediate Release                                            9 NOVEMBER 2007


 OXFORD BIOMEDICA ANNOUNCES APPOINTMENT OF JPMORGAN CAZENOVE AS SOLE CORPORATE
                       BROKER AND JOINT FINANCIAL ADVISER


Oxford, UK - 9 November 2007: Oxford BioMedica (LSE: OXB), a leading gene
therapy company, today announces that it has appointed JPMorgan Cazenove Limited
as its sole corporate broker and joint financial adviser with immediate effect.

                                     -Ends-



For further information, please contact:

Oxford BioMedica plc:                                   Tel: [phone]
Professor Alan Kingsman, Chief Executive

JPMorgan Cazenove Limited                               Tel: [phone]
James Mitford/Gina Gibson

City/Financial Enquiries:                               Tel: [phone]
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications

Scientific/Trade Press Enquiries:                       Tel: [phone]
Gemma Price/ Holly Griffiths/ Katja Stout
Northbank Communications


Notes to editors

1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development and commercialisation of novel therapeutic vaccines and gene-based
therapies with a focus on oncology and neurotherapy. The Company was established
in 1995 as a spin-out from Oxford University, and is listed on the London Stock
Exchange.

The Company has a platform of gene delivery technologies, which are based on
highly engineered viral systems. Oxford BioMedica also has in-house clinical,
regulatory and manufacturing know-how. In oncology, the lead product candidate
is TroVax(R), an immunotherapy for multiple solid cancers, which is licensed to
sanofi-aventis for global development and commercialisation. A Phase III trial
of TroVax in renal cancer is ongoing and two Phase III trials in colorectal
cancer are planned. Oxford BioMedica has two other anti-cancer product
candidates in Phase II development for melanoma and pancreatic cancer
respectively. In neurotherapy, the Company has submitted a Clinical Trial
Application to initiate a Phase I/II trial of its gene-based treatment for
Parkinson's disease, ProSavin(R). The neurotherapy pipeline also includes
preclinical gene-based therapeutics for vision loss, motor neuron disease and
nerve repair.

The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 80 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners
include sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibody
therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and
Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline
and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange